Personalized Cancer Vaccine Summit

Kongressthemen
With recent advancements into Phase II and III trials for personalized cancer vaccines along with 437 other candidates in development, the biopharma industry is at a critical point to demonstrate safe and efficacious results that will offer a real hope for every patient with a cure for cancer.

Kongressorganizer (PCO)
Hanson Wade

Anmerkungen
URL:
Brochure: https://go.evvnt.com/2558274-3?pid=4832

Speakers: Agnete Fredriksen, Chief Scientific Officer, Nykode Therapeutics, Charles Link, Chief Medical Officer, Syncromune, David Berd, Chief Medical Officer, Biovaxys, and more

https://go.evvnt.com/2558274-2?pid=4832

Frau Isabel Weir